Pfizer's CEO Albert Bourla has previously said that the pharmaceutical giant could be ready to file for regulatory approval of the shot by March.
"We recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," she said. "This study is part of our science-based approach to develop a variant-based vaccine that achieves a similar level of protection against Omicron as it did with earlier variants but longer duration of protection."A spokesperson for Pfizer said that it did not include people older than 55 because the goal of the study was to examine the immune response of participants dosed, rather than estimate vaccine efficacy.
The second will be people who got three doses of the current vaccine 90-180 days prior to the study and will receive either another dose of the original shot or an Omicron-specific vaccine.The third and final group are people who have never previously received a Covid vaccine, and will receive three doses of the Omicron-specific vaccine.Because it is based on messenger RNA technology, it is relatively easy to update to reflect the genetic code of new variants.
When will people ever learn that they will never be able to catch up with the latest virus strain. Its the same mistake they are making again as with Alpha strain. In the end docile civilians are the guinea pigs for these live RCT experiments which only profit Big Pharma pockets.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: STForeignDesk - 🏆 4. / 71 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: STForeignDesk - 🏆 4. / 71 Read more »